Boston Scientific Corporation

Boston Scientific Corporation

BSXยทNYSE

$47.69

+0.021%
HealthcareMedical - Devices

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

At a Glance

Live Snapshot
Market Cap$70.88B
EPS1.9600
P/E Ratio24.33
Earnings Date07/22/2026
3Y+197.0%
5Y+201.0%
10Y+366.0%
3Y+31.0%
5Y+542.0%
10Y+198.0%
3Y-28.0%
5Y-235.0%
10Y+92.0%
BSX

Boston Scientific Corporation Cash Conversion Engine

BSX ยท NYSE
Net Income2.89B
Depreciation & Amortization1.37B
Stock-Based Compensation299.00M
Change in Working Capital-246.00M
Others221.00M
Capital Expenditures-876.00M
Free Cash Flow3.66B

Cash Flow Quality Analysis

FCF Conversion Rate

126.5%

Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.

CapEx Intensity

19.3%

Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.

FCF Growth Trend

+38.3%

Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.

Working Capital Impact

-$246.00M

Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.

Cash Flow Quality Insight

Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.

Boston Scientific Corporation Cash Flow Statement

BSX โ€ข NYSE

Boston Scientific Corporation Cash Flow StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011Dec 2010Dec 2009Dec 2008Dec 2007Dec 2006
OPERATING ACTIVITIES
2.9B
1.8B
1.6B
698M
1B
-82M
4.7B
1.7B
104M
347M
-239M
-119M
-121M
-4.1B
441M
-1.1B
-1B
-2B
-495M
-3.6B
1.4B
1.3B
1.2B
1.1B
1.1B
1.1B
1B
894M
844M
815M
769M
725M
689M
683M
717M
816M
834M
864M
939M
781M
0.0
0.0
-1M
-63M
-124M
-82M
-4.3B
-87M
245M
-305M
-532M
-397M
-223M
-166M
46M
-110M
-64M
-334M
-386M
-420M
299M
266M
233M
220M
194M
170M
157M
140M
127M
116M
107M
103M
105M
108M
128M
150M
144M
138M
122M
0.0
221M
516M
253M
540M
18M
337M
551M
-148M
40M
3M
215M
-5M
477M
4.4B
-87M
1.9B
24M
2.7B
712M
4.7B
(0.0)
(656M)
(512M)
(662M)
(302M)
(207M)
(242M)
(1B)
(0.0)
(94M)
(80M)
(74M)
(67M)
(97M)
(138M)
(286M)
(46M)
(468M)
(475M)
(0.0)
-246M
-462M
-770M
-1B
-351M
42M
-282M
-2.2B
66M
-4M
280M
962M
155M
284M
-237M
-1.4B
922M
-77M
42M
355M
4.5B
3.4B
2.5B
1.5B
1.9B
1.5B
1.8B
310M
1.4B
972M
600M
1.3B
1.1B
1.3B
1B
325M
835M
1.2B
934M
1.8B
INVESTING ACTIVITIES
-876M
-790M
-711M
-612M
-554M
-376M
-461M
-316M
-319M
-376M
-247M
-259M
-245M
-226M
-304M
-278M
-362M
-362M
-363M
-341M
-1.6B
-4.6B
-1.8B
-1.5B
-1.4B
(12M)
-4.3B
-1.4B
-560M
-408M
-1.7B
-474M
-244M
-356M
(1.1B)
-211M
-527M
(535M)
-261M
-9.1B
(0.0)
(0.0)
(0.0)
-24M
(96M)
-146M
-348M
-172M
-131M
-132M
-266M
-26M
-44M
-22M
-11M
(6M)
(50M)
-147M
-2M
-98M
0.0
0.0
0.0
56M
294M
12M
59M
14M
131M
0.0
61M
14M
5M
9M
5M
4M
91M
149M
243M
192M
-171M
-257M
-52M
106M
-1M
87M
1M
1M
-131M
29M
0.0
0.0
53M
16M
16M
-1M
-45M
149M
-91M
18M
-2.6B
-5.7B
-2.6B
-2B
-1.6B
-411M
-5B
-1.9B
-1B
-887M
-2.2B
-745M
-475M
-579M
(769M)
-480M
-793M
(324M)
-474M
-9.3B
FINANCING ACTIVITIES
282M
230M
182M
136M
110M
440M
123M
101M
85M
111M
114M
-65M
-426M
-579M
-471M
31M
33M
71M
72M
1.5B
-491M
1.8B
-4M
-165M
0.0
-999M
2.8B
1.4B
123M
-190M
1.4B
0.0
-10M
-19M
-1.3B
-527M
-853M
-1.4B
-754M
6.9B
(0.0)
(0.0)
-28M
-55M
-55M
-28M
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(136M)
(0.0)
-535M
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
-125M
-500M
-600M
-492M
(0.0)
(0.0)
(0.0)
-60M
(0.0)
-186M
-243M
-145M
-464M
-150M
-95M
56M
-74M
-98M
-127M
-177M
-85M
-160M
-146M
0.0
0.0
0.0
4M
2M
6M
-395M
1.8B
5M
-548M
-95M
293M
3B
1.4B
110M
-206M
1.3B
-150M
-596M
-744M
-1.7B
-496M
-820M
-1.4B
-680M
8.4B
CASH FLOW SUMMARY
42M
-11M
-16M
-9M
-8M
-2M
10M
-11M
4M
-2M
-4M
-4M
-1M
3M
-2M
0.0
1M
-1M
4M
7M
1.5B
-449M
-82M
-1B
171M
1.4B
-222M
-190M
530M
-123M
-268M
370M
10M
-60M
54M
-651M
-777M
189M
-216M
979M
606M
1.1B
1.1B
2.2B
2B
607M
829M
1B
487M
319M
587M
217M
207M
267M
213M
864M
1.6B
1.5B
1.7B
689M
2.1B
606M
995M
1.1B
2.2B
2B
607M
829M
1B
196M
319M
587M
217M
207M
267M
213M
864M
1.6B
1.5B
1.7B
3.7B
2.6B
1.7B
914M
1.3B
1.1B
1.4B
-6M
1.1B
596M
353M
1B
837M
1B
704M
47M
473M
854M
571M
1.5B

SEC Filings

BSX - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

May 18, 2026
May 18, 2026
2026
8-K

8-K 2026

N/A

May 18, 2026
May 18, 2026
2026
8-K

8-K 2026

N/A

May 05, 2026
April 30, 2026
2026
10-Q

10-Q 2026 Q1

Q1

May 01, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

April 22, 2026
April 22, 2026
2026
S-4/A

S-4/A (Amended)

N/A

March 30, 2026
March 30, 2026
ย 
8-K

8-K 2026

N/A

March 30, 2026
March 28, 2026
2026
DEF 14A

DEF 14A 2026

N/A

March 18, 2026
March 18, 2026
2026
S-4

S-4

N/A

February 27, 2026
February 27, 2026
ย 
8-K

8-K 2026

N/A

February 26, 2026
February 26, 2026
2026
Showing 1 to 10 of 602 filings